Chronic Kidney Disease Staging and Management
Key Points
- Chronic kidney disease (CKD) is progressive loss of kidney function with impaired fluid and waste regulation.
- CKD staging is based on glomerular filtration rate (GFR), from Stage 1 at 90 or higher to Stage 5 below 15 mL/min/1.73 m2.
- Typical CKD laboratory trends include increased creatinine and BUN, decreased GFR, elevated potassium and phosphorus, and decreased calcium.
- Advanced disease may require dialysis or kidney transplantation to maintain life and metabolic stability.
- Renal nutrition plans commonly limit sodium, potassium, phosphorus, and sometimes protein to reduce toxin/mineral accumulation and symptom burden.
- Nursing priorities focus on fluid and electrolyte balance, blood pressure control, medication safety, and self-management support.
Pathophysiology
CKD is a gradual, long-term decline in renal function that reduces filtration, fluid regulation, and endocrine roles of the kidneys. As function worsens, waste products and excess fluid accumulate, and dysregulation of electrolyte and hormone systems creates multisystem complications.
Disease progression is influenced by reduced renal perfusion and direct kidney injury from conditions such as diabetes, hypertension, heart disease, obesity, smoking/tobacco exposure, atherosclerosis, glomerular disorders, recurrent urinary tract infection, kidney stones, prolonged urinary obstruction, autoimmune disease, and chronic nephrotoxic medication exposure.
Risk burden is higher in older adults (especially over 40), those with family history of CKD, clients with abnormal kidney structure, and populations with elevated CKD prevalence, including African American, Hispanic, Native American, and Asian American groups.
Classification
- Stage 1: Normal GFR, 90 or higher mL/min/1.73 m2.
- Stage 2: Mild reduction in GFR, 60-89 mL/min/1.73 m2.
- Stage 3: Moderate reduction in GFR, 30-59 mL/min/1.73 m2.
- Stage 4: Severe reduction in GFR, 15-29 mL/min/1.73 m2.
- Stage 5: Kidney failure (end-stage), below 15 mL/min/1.73 m2.
Nursing Assessment
NCLEX Focus
Prioritize trend recognition for renal decline, fluid overload, and high-risk electrolyte abnormalities.
- Assess for progressive symptoms such as weakness/fatigue, dyspnea, generalized edema (including puffiness around the eyes), appetite decline, concentration difficulty, urination-pattern changes, pruritus, and metallic taste.
- Watch for frequent urge to void with increasingly small urine amounts as a potential worsening renal-failure cue.
- Monitor blood pressure, intake/output, daily weight trends, and signs of fluid overload or dehydration.
- Trend kidney function and electrolyte labs, including creatinine, BUN, GFR, potassium, phosphorus, calcium, and CBC for anemia.
- Assess cardiovascular complications, including edema-related hypertension, dysrhythmia risk with hyperkalemia, heart-murmur changes from overload states, and advanced-stage pericarditis cues.
- Assess multisystem complications, including cognitive change from uremia, GI bleeding risk from platelet dysfunction, and musculoskeletal decline such as muscle cramping or renal osteodystrophy-related bone pain/fracture risk.
- Review urinalysis patterns (protein, blood, infection cues) and diagnostic-imaging plans (ultrasound, CT, or biopsy) when evaluating structural causes, obstruction, or tumor.
- Review dialysis access status and signs of access complications when renal replacement therapy is in use.
- Assess CKD risk-profile domains explicitly (diabetes, hypertension, obesity, tobacco use, family history, and congenital/structural kidney abnormalities) to prioritize prevention teaching and surveillance cadence.
Nursing Interventions
- Implement stage-appropriate fluid and electrolyte management with prescribed restrictions and frequent reassessment.
- Administer and monitor medications for blood pressure control, anemia support, and electrolyte correction.
- For CKD-associated low erythropoietin states, support ordered erythropoiesis-stimulating therapy and trend hemoglobin response with renal-team guidance.
- Reinforce renal nutrition strategy with sodium, potassium, phosphorus, protein, and fluid guidance (for sodium, often about 1,500-2,300 mg/day depending on plan).
- Reinforce practical renal-portion anchors when ordered (for example many plans limit protein servings to about 2-3 oz per meal and use stage-based fluid targets, often around 2,000 mL/day before tighter advanced-stage limits).
- Coordinate early dietitian referral for individualized CKD meal planning to delay progression, reduce complications, and improve quality of life.
- Coordinate dialysis care and reinforce adherence to treatment schedules and pre/post treatment monitoring.
- During prescribed fluid restriction, provide dry-mouth comfort strategies such as hard candy, ice chips, or breath spray when allowed by plan/policy.
- Reinforce smoking-cessation support and diabetes glucose-control adherence to reduce ongoing renal injury risk.
- Support transplant-readiness pathways for eligible end-stage clients and reinforce lifelong immunosuppressant adherence after transplantation.
- Provide health teaching on nephrotoxic medication avoidance, daily weight surveillance (including dialysis-day weights), early symptom reporting, and psychosocial coping resources such as support groups.
End-Stage Decompensation Risk
Late-stage CKD can rapidly destabilize through fluid overload, severe electrolyte disturbance, dysrhythmia, and uremic complications.
Pharmacology
| Drug Class | Examples | Key Nursing Considerations |
|---|---|---|
| ace-inhibitors | class-based agents | Support blood pressure and kidney protection; monitor tolerance. |
| angiotensin-ii-receptor-blockers | class-based agents | Alternative blood pressure and renal-protection pathway. |
| hematopoietic-growth-factors | class-based agents | Address CKD-related anemia; trend hemoglobin response. |
| phosphate-binders | class-based agents | Reduce phosphorus absorption to support mineral balance. |
| potassium-lowering-agents | sodium polystyrene | Used for hyperkalemia risk reduction with ongoing lab reassessment. |
| calcium-supplements | class-based agents | Support calcium replacement when CKD-related hypocalcemia is present. |
Clinical Judgment Application
Clinical Scenario
A client with Stage 4 CKD presents with worsening edema, rising blood pressure, dyspnea on exertion, and lab trends showing falling GFR with elevated potassium and phosphorus.
- Recognize Cues: Fluid overload signs plus worsening renal and electrolyte trends.
- Analyze Cues: Progressive renal decline is increasing cardiopulmonary and dysrhythmia risk.
- Prioritize Hypotheses: Highest priority is preventing life-threatening decompensation from fluid and potassium imbalance.
- Generate Solutions: Intensify monitoring, optimize medications, and reinforce fluid/electrolyte restrictions.
- Take Action: Implement provider orders, monitor closely, and escalate deterioration promptly.
- Evaluate Outcomes: Edema and blood pressure improve, and critical electrolyte values stabilize.
Related Concepts
- diabetes-mellitus - Major upstream contributor to CKD progression and vascular injury.
- hypertension-assessment-and-management - Shared blood pressure-control priority to reduce renal decline.
- peritoneal-and-hemodialysis-nursing-management - Renal replacement pathway for Stage 5 kidney failure.
- fluid-volume-overload-hypervolemia - Common CKD consequence requiring active surveillance.
- potassium-balance-disorders - Hyperkalemia risk in CKD with potential dysrhythmia complications.
Self-Check
- Which GFR ranges define CKD Stages 3, 4, and 5?
- Which laboratory pattern most strongly suggests progressive CKD with mineral imbalance?
- Why are fluid, electrolyte, and blood pressure trends central to CKD safety monitoring?